Navigation Links
Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
Date:3/19/2013

nse, offset by a $0.9 million decrease in consulting fees and legal expenses.

Balance Sheet Highlights
As of December 31, 2012, the Company had cash, cash equivalents and short-term investments totaling $36.5 million. Stockholders' equity amounted to $41.8 million as of December 31, 2012.  The Company's contingent asset related to the consideration for the acquisition of SynthRx in April 2011 was settled in December 2012.  The Company recorded the fair value of the contingent asset as of the settlement date as an adjustment to equity and recognized as a transaction-related expense the increase in its fair value as of its settlement date relative to December 31, 2011.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, CA.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is recruiting subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are
'/>"/>

SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Achieves ISO 13485 Certification
2. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
3. Echo Therapeutics Appoints Robert Doman to Board of Directors
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
7. PTC Therapeutics Closes $60 Million Private Financing
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
10. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... June 30, 2014. "The second ... Semler," said Doug Murphy-Chutorian , M.D., chief ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
(Date:7/27/2014)... 27, 2014 The European Bromine market report ... and forecast of revenue. , Bromine market in European region ... and UK. Germany and France that forms a dominant share ... derivatives in Europe. , Browse through the TOC of ... the in-depth analysis provided Browse through the TOC of the ...
(Date:7/27/2014)... Australia (PRWEB) July 27, 2014 ... in Australia is restricted to two companies, heavy ... to IBISWorld industry analyst Spencer Little, “Demand for ... due to rising health concerns, frequent anti-smoking campaigns, ... result, industry revenue is estimated to fall at ...
(Date:7/27/2014)... 2014 iFitDress.com, a well-known wedding dress ... of wedding gowns with sleeves . Furthermore, it ... they are now available with big discounts, from 20 ... that iFitDress.com is one of the big players in ... the new wedding gowns feature fine craftsmanship and charming ...
(Date:7/27/2014)... Alta Resources , a global provider of ... brands, announced today that it plans to fill more ... Florida and the Philippines. , A majority of the ... seasonal ramp-ups that require additional staffing in preparation for ... 2015. As more consumers become eligible for health-plan coverage ...
(Date:7/27/2014)... Individuals that have been involved in an ... the newly released ebook guide for how to ... help those struggling through the aftermath of personal injury due ... guide attempts to help individuals understand the legal process and ... of their doctors and an experienced attorney. , Contact ...
Breaking Medicine News(10 mins):Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Auto Accident Personal Injury Ebook Guide Released by The Jones Firm 2
... In some cases, an apple a day may keep the ... may also do the job. A new study by ... the use of Aspirin as a preventative measure for cardiovascular ... collected data from clinical trials that looked at whether taking ...
... 5 (HealthDay News) -- Small rural hospitals in the United ... patient outcomes than larger hospitals, a new study finds. ... beneficiaries in order to assess the care provided by critical ... care beds and are located more than 35 miles from ...
... ROCHESTER, Minn. For nearly two decades, the medical ... lightning-rod topic of stem cells, in particular the controversy ... years ago successfully "reprogrammed" adult body cells to become ... over. Those redirected cells, known as induced pluripotent cells, ...
... HealthDay Reporter , TUESDAY, July 5 (HealthDay News) ... for easing low back pain in the short term, a ... mostly middle-aged, female and white, all of whom had chronic ... of either relaxation massage or structural massage were better able ...
... More breast cancer patients than previously believed may ... of Michigan Comprehensive Cancer Center study shows. Researchers ... whether cancer patients receive appropriate care and found that ... cancer patients undergo radiation treatments. The Surveillance ...
... Society invites you to attend the 2012 Symposium on ... held March 12-14, 2012, at the Marriott Baltimore Waterfront ... exciting first-time event. The symposium aims to bring ... and practice realms of the health-care community and to ...
Cached Medicine News:Health News:Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes 2Health News:Small, Rural Hospitals Provide a Lower Quality of Care: Study 2Health News:Moving beyond embryonic stem cells: Encouragement on the horizon 2Health News:Massage Beats Meds for Lower Back Pain, Study Says 2Health News:Radiation rates for breast cancer may be underestimated, U-M study finds 2Health News:HFES sponsors 2012 Symposium on Human Factors and Ergonomics in Health Care 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
Medicine Products: